Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$36 Mln
P/E Ratio
--
P/B Ratio
6.02
Industry P/E
92.42
Debt to Equity
0.85
ROE
-2.21 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-0.92
CFO
$-45.88 Mln
EBITDA
$-47.30 Mln
Net Profit
$-51.37 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Femasys Inc (FEMY)
| 39.09 | -3.77 | 34.21 | -18.62 | -9.87 | -- | -- |
|
BSE Sensex
| -3.77 | -0.92 | -6.67 | 3.66 | 9.18 | 19.75 | 10.11 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Femasys Inc (FEMY)
| 12.71 | 8.33 | -76.92 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 17.05 | 11,098.72 | 15.67 | 12.69 | |
| 71.47 | 9,770.98 | 94.72 | 2.52 | |
| 168.78 | 9,074.73 | -- | -25.23 | |
| 273.56 | 10,500.20 | 778.91 | 1.2 |
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and... Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia. Address: 3950 Johns Creek Court, Suwanee, GA, United States, 30024 Read more
Founder, President, CEO & Director
Ms. Kathy Lee-Sepsick M.B.A.
Founder, President, CEO & Director
Ms. Kathy Lee-Sepsick M.B.A.
Headquarters
Suwanee, GA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Femasys Inc (FEMY) stood at $ 18 Mln as on 30-Sep-24
The share price of Femasys Inc (FEMY) is $1.53 (NASDAQ) as of 18-Mar-2025 14:32 EDT. Femasys Inc (FEMY) has given a return of -9.87% in the last 3 years.
Femasys Inc (FEMY) has a market capitalisation of $ 36 Mln as on 17-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Femasys Inc (FEMY) is 6.02 times as on 17-Mar-2025, a 62% premium to its peers’ median range of 3.72 times.
Since, TTM earnings of Femasys Inc (FEMY) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Femasys Inc (FEMY) and enter the required number of quantities and click on buy to purchase the shares of Femasys Inc (FEMY).
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia. Address: 3950 Johns Creek Court, Suwanee, GA, United States, 30024
The CEO & director of Ms. Kathy Lee-Sepsick M.B.A.. is Femasys Inc (FEMY), and CFO & Sr. VP is Ms. Kathy Lee-Sepsick M.B.A..
There is no promoter pledging in Femasys Inc (FEMY).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,103
|
|
|
1,084
|
|
|
1,055
|
|
|
990
|
| Femasys Inc (FEMY) | Ratios |
|---|---|
|
Return on equity(%)
|
-167.8
|
|
Operating margin(%)
|
-1331.19
|
|
Net Margin(%)
|
-1436.04
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Femasys Inc (FEMY) was $0 Mln.
$-0.07
(
